title: Etoposide and mitomycin-C in pretreated metastatic breast cancer.
abstract: Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i.v. days 1 to 5 every 21 days and mitomycin-C 10 mg/m2 i.v. day 1 every 42 days. A partial response (PR) occurred in 10 patients with an overall response rate of 40% (47% when only the 21 patients evaluable after 3 courses or more were considered). The median duration of PR was 10.5 months (range 3-31). The soft tissue metastatic sites were the most responsive. Toxicity was mild.
authors.affiliation: Oncologia Clinica, Università di Ancona, Italy.
authors.forename: E T
authors.initials: ET
authors.lastname: Menichetti
authors.forename: R R
authors.initials: RR
authors.lastname: Silva
authors.forename: D
authors.initials: D
authors.lastname: Tummarello
authors.forename: S
authors.initials: S
authors.lastname: Miseria
authors.forename: U
authors.initials: U
authors.lastname: Torresi
authors.forename: R
authors.initials: R
authors.lastname: Cellerino
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D005047:Etoposide